Gomez DR, Blumenschein GR Jr, Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682. https://doi.org/10.1016/S1470-2045(16)30532-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501

Article  PubMed  Google Scholar 

Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs Stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650–659. https://doi.org/10.1001/jamaoncol.2020.0147

Article  PubMed  PubMed Central  Google Scholar 

Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830–2838. https://doi.org/10.1200/JCO.20.00818

Article  PubMed  PubMed Central  Google Scholar 

Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453. https://doi.org/10.1200/JCO.2017.75.4853

Article  CAS  PubMed  Google Scholar 

Macchia G, Lazzari R, Colombo N et al (2020) A large, multicenter, retrospective study on efficacy and safety of Stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and maNGO groups. Oncologist 25(2):e311–e320. https://doi.org/10.1634/theoncologist.2019-0309

Article  PubMed  Google Scholar 

Macchia G, Pezzulla D, Campitelli M et al (2023) Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer (MITO-RT2/RAD STUDY): a large, real-world study in collaboration with AIRO GYN, MITO and MaNGO Groups. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2023.04.025

Article  PubMed  Google Scholar 

Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021–1031

Article  CAS  PubMed  Google Scholar 

Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095–1101

Article  CAS  PubMed  Google Scholar 

D’Souza WD, Thames HD (2001) Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51:1–3

Article  PubMed  Google Scholar 

Dasu A (2007) Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 19:289–301

Article  CAS  Google Scholar 

Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060

Article  PubMed  PubMed Central  Google Scholar 

Incrocci L, Wortel RC, Alemayehu WG et al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17:1061–1069

Article  PubMed  Google Scholar 

Lee WR, Dignam JJ, Amin MB et al (2016) Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34:2325–2332

Article  PubMed  PubMed Central  Google Scholar 

Catton CN, Lukka H, Gu CS et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884–1890

Article  CAS  PubMed  Google Scholar 

Quon HC, Ong A, Cheung P et al (2018) Once weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a phase 2 randomized trial. Radiother Oncol 127:206–212. https://doi.org/10.1016/j.radonc.2018.02.029

Article  PubMed  Google Scholar 

Widmark A, Gunnlaugsson A, Beckman L et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394:385–395. https://doi.org/10.1016/S0140-6736(19)31131-6

Article  PubMed  Google Scholar 

Kim DWN, Cho LC, Straka C et al (2014) Predictors of rectal tolerance observed in a dose-escalated phase 1–2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89:509–517. https://doi.org/10.1016/j.ijrobp.2014.03.012

Article  PubMed  Google Scholar 

Boike TP, Lotan Y, Cho LC et al (2011) Phase I dose escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol 29:2020–2026. https://doi.org/10.1200/JCO.2010.31.4377

Article  PubMed  PubMed Central  Google Scholar 

Tree AC, Ostler P, van der Voet H et al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2‑year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23(10):1308–1320. https://doi.org/10.1016/S1470-2045(22)00517-4

Article  PubMed  Google Scholar 

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer, Version 1.2023

Cellini N, Morganti AG, Mattiucci GC et al (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53(3):595–599. https://doi.org/10.1016/s0360-3016(02)02795-5

Article  PubMed  Google Scholar 

Dickinson L, Ahmed HU, Allen C et al (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59:477–494. https://doi.org/10.1016/j.eururo.2010.12.009

Article  PubMed  Google Scholar 

Lee J, Carver E, Feldman A et al (2019) Volumetric and voxel-wise analysis of dominant Intraprostatic lesions on multiparametric MRI. Front Oncol 9:616. https://doi.org/10.3389/fonc.2019.00616

Article  PubMed  PubMed Central  Google Scholar 

Ciabatti S, Ntreta M, Buwenge M et al (2019) Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study. Med Dosim 44(4):356–364

Article  PubMed  Google Scholar 

Aluwini S, van Rooij P, Hoogeman M et al (2013) Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol 8:84. https://doi.org/10.1186/1748-717X-8-84

Article  PubMed  PubMed Central  Google Scholar 

McDonald AM, Dobelbower MC, Yang ES et al (2018) Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: acute toxicity and dosimetry results from a prospective trial. Adv Radiat Oncol 4(1):90–95. https://doi.org/10.1016/j.adro.2018.09.007

Article  PubMed  PubMed Central  Google Scholar 

Draulans C, van der Heide UA, Haustermans K et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high-risk prostate cancer. Radiother Oncol 147:92–98. https://doi.org/10.1016/j.radonc.2020.03.015

Article  PubMed  Google Scholar 

Herrera FG, Valerio M, Berthold D et al (2019) 50-Gy stereotactic body radiation therapy to the dominant Intraprostatic nodule: results from a phase 1a/b trial. Int J Radiat Oncol Biol Phys 103(2):320–334. https://doi.org/10.1016/j.ijrobp.2018.09.023

Article  PubMed  Google Scholar 

Kotecha R, Djemil T, Tendulkar RD et al (2016) Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes. Int J Radiat Oncol Biol Phys 95(3):960–964. https://doi.org/10.1016/j.ijrobp.2016.02.009

Article  PubMed  Google Scholar 

Macchia G, Cilla S, Deodato F et al (2016) Simultaneous integrated boost volumetric modulated arc therapy in the postoperative treatment of high-risk to intermediate-risk endometrial cancer: results of ADA II phase 1–2 trial. Int J Radiat Oncol Biol Phys 96(3):606–613. https://doi.org/10.1016/j.ijrobp.2016.07.004

Article  PubMed  Google Scholar 

Cilla S, Deodato F, Digesù C et al (2014) Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high risk prostate and rectal cancer cases. Med Dosim 39(1):108–116. https://doi.org/10.1016/j.meddos.2013.11.001

Article  PubMed  Google Scholar 

Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. J Urol 148(5):1549–1557

Article  CAS  PubMed  Google Scholar 

Weinreb JC, Barentsz JO, Choyke PL et al (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69(1):16–40

Article  PubMed  Google Scholar 

Ma TM, Emami B, Grimm J et al (2019) Volume effects in radiosurgical spinal cord dose tolerance: how small is too small? J Radiat Oncol 1:53–61

Article  Google Scholar 

Chang P, Szymanski KM, Dunn RL et al (2011) Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 186(3):865–872. https://doi.org/10.1016/j.juro.2011.04.085